Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike Glycoprotein S1 Subunit Receptor-Binding Domain (RBD)
- Target
- RBD
- Molecular classification
- Glycoprotein, Viral protein, Receptor binding domain
01
Overview
The receptor-binding domain (RBD) of the S1 subunit of the coronavirus spike glycoprotein is responsible for binding to the ACE2 receptor on host cells, initiating viral entry. It is a major target for neutralizing antibodies and vaccines. The RBD's conformation switches between "up" (accessible) and "down" (hidden) states to modulate receptor binding. Mutations within the RBD can affect binding affinity, antibody evasion, and viral infectivity.
- Other names
- Spike RBDS1 RBDReceptor-binding domain of SARS-CoV-2 Spike protein
02
Mechanism of action
Binding to ACE2 receptor inhibits viral entry; antibodies block RBD-ACE2 interaction.
03
Biological functions
Receptor bindingViral entryImmune evasion
04
Disease associations
InfectionCOVID-19
05
Safety considerations
Potential for antibody-dependent enhancement (ADE)Evasion of neutralizing antibodies by mutationsOff-target effects of ACE2 modulating therapies
06
Interacting drugs
Neutralizing antibodies
2 more in the full profile.
07
Biomarkers
Anti-RBD antibody titers (vaccine efficacy, prior infection)RBD mutations (resistance to antibodies)
Beyond the preview
Go deeper on Spike Glycoprotein S1 Subunit Receptor-Binding Domain (RBD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike Glycoprotein S1 Subunit Receptor-Binding Domain (RBD).